Disordered coagulation is encountered in up to 90% of cancer patients, although only 15% of them develop either a localised acute or chronic deep venous thrombosis or a disseminated intravascular coagulation.
Furthermore, the incidence of DVT in solid tumours is difficult to establish because most clinical studies presented in current literature show a great variability based on the type of diagnostic procedure performed (clinical alone or clinical and objective testing as venography), the most frequent tumour histotype, the medical or surgical procedure and, finally, the presence of an indwelling central venous catheter, which in itself increases the risk of thrombosis of the axillary/subclavian vein. 2 Clinical conditions associated with a higher incidence of DVT (surgical interventions, immobility, chronic obstructive lung disease, cardiac failure, estrogen-progesterone use, pregnancy, puerperium) raise the already elevated risk of thromboembolism in cancer patients. From a clinical point of view, DVT of the lower limbs is the most common clinical manifestation of thromboembolic disease. Even though pancreatic adenocarcinoma has classically been associated with a higher risk of DVT, the distribution of specific cancers associated with thrombosis follows the frequency of the cancer in the general population. More recent data show that the highest incidence in men is observed in patients with lung, prostate and colorectal cancer and in women with breast, ovarian and lung cancer. 3, 4 Patients with cancer are clearly at high risk of developing venous thromboembolism (VTE), particularly during chemotherapy and surgery. This is aggravated by the use of venous access catheters and possibly by growth factors. 5, 6 No studies have been able to quantify definitively the risk of developing a DVT for each histotype and/or site of the primary tumour. In addition, although the best way to evaluate the true incidence of clinical VTE is through prospective cohort studies, most data in the literature have been derived from retrospective and prospective studies not specifically designed to evaluate the issue.
The developing of VTE is a multifactorial event involving several mechanisms.
General mechanisms include inflammation due to necrosis or release of acute-phase reactants and haemodynamic disorder such as stasis. Tumourspecific mechanisms include the capacity of tumour cells to activate the coagulation cascade in several ways. The tumour cells are able to interact with host blood cells such as platelets, leukocytes and endothelial cells by releasing inflammatory cytokines -interleukin (IL)-1, tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF) -or by direct cell-to-cell interactions. This results in a downregulation of anticoagulant and an upregulation of procoagulant properties of these cells, contributing to the general hypercoagulable condition of these subjects. 7 Cancer cells also produce a number of procoagulant substances, including tissue factor [8] [9] [10] [11] and cancer procoagulant. 12, 13 Therefore, tumour tissue can directly activate the clotting cascade, leading to thrombin generation and fibrin formation.
Tissue factor and other haemostatic proteins, including thrombin and fibrin, besides favouring thrombotic phenomenon, are also involved in the neoplastic dissemination and metastasis. 14 
Venous Thromboembolism During Chemotherapy or

Hormone Therapy
The relation between VTE and chemotherapy has been most extensively investigated in patients with breast cancer. The risk of DVT in early-stage breast cancer patients under clinical control varies from 0.2 to 0.8%, whereas in patients who received adjuvant therapy the risk ranges from 2 to 10%, reaching 17.6% in stage IV disease. 2 Levine et al. 15 demonstrated that chemotherapy contributes to thrombosis in patients with breast cancer. Tables 1 and 2 show some of the available data on DVT incidence associated with adjuvant hormone therapy and/or chemotherapy in patients with radically resected breast cancer. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The limitations of these studies derive from the lack in many cases of a control population or the accurate instrumental diagnosis of DVT or pulmonary embolism. Tamoxifen raises the risk of developing a thromboembolism regardless of the presence of a neoplasm or use of chemotherapy. The risk of thromboembolism in patients taking tamoxifen as adjuvant treatment is 1-2%. This risk is much higher in women undergoing chemo-endocrine therapy, reaching 13%. 19 Moreover, the risk is increased in post-menopausal women. 
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Oncology-related Complications
Saphner et al. 24 showed that the frequency of thrombosis, both venous and arterial combined, was 5.4% among patients who received adjuvant therapy and 1.6% among patients without chemotherapy (p=0.0002).
Pre-menopausal patients who received chemotherapy and tamoxifen had significantly more venous complications than those who received chemotherapy without tamoxifen (2.8 versus 0.8%; p=0.03). Postmenopausal patients who received tamoxifen and chemotherapy had an showed an economic gain using low doses of warfarin to prevent major thromboembolic complications. 39 Nevertheless, the event rate in this study was quite low (4.4 versus 0.6% in the study and control group, respectively); as a consequence, the prophylaxis should be tailored and individualised. There is no evidence in favour of extensive prophylaxis for cancer patients receiving chemotherapy in an outpatient setting.
The final results of several ongoing studies (Topic I, II, Protecht, Prodige)
will be important in order to draw conclusions in this setting.
Venous Thromboembolism and Cancer -Implications for the Prognosis
The association between venous thrombosis and tumours, although first have been recently reviewed. 40, 41 The VA Co-operative study #75 reported, in a controlled, randomised trial, that warfarin may favourably modify the course of some human malignancy, including small-cell lung cancer. 42 This study has been well conducted, but as the accrual of patients affected by small cell lung carcinoma was very limited (50 patients), it is hard to draw firm conclusions.
Kakkar and colleagues conducted the first randomised, placebo-controlled trial of LMWH in patients with advanced solid tumour malignancy without evidence of underlying thrombosis, with the primary objective of determining effect on survival at one year. 43 The authors took into consideration previous studies that suggested that LMWH therapy may prolong survival in patients with cancer. 44, 45 The effectiveness of LMWH (dalteparin) 5,000UI/die s.c. in patients with small-cell lung cancer, given in combination with chemotherapy versus chemotherapy alone, was recently evaluated by Altinbas et al. 46 The results showed that at 18 weeks the overall tumour response rate was significantly higher in patients receiving chemotherapy plus LMWH compared with those receiving chemotherapy alone. The median progress free survival was also significantly prolonged with the addition of LMWH (10 versus six months; p=0.01).
Two recently reported prospective, randomised, placebo-controlled trials, evaluating specifically LMWHs for survival in cancer patients, confirmed a survival benefit for patients with a good prognosis. 43, 47 However, the subgroup analysis performed in the Famous study was a post hoc analysis, not specified a priori. 43 Recently, the survival data were examined in a post hoc analysis in patients with solid tumours and VTE who were randomly assigned to dalteparin or a coumarin derivative for six months in a multicentre, open-label, randomised, controlled trial (CLOT Study). 48 The use of dalteparin relative to coumarin derivatives was associated with improved survival in patients with solid tumours who did not have metastatic disease at the time of an acute VTE event.
In conclusion, all the aforementioned data clearly indicate that knowledge of the role of the coagulation cascade in cancer development and the subsequent rational approach in clinical practice will allow us to better comprehend the genesis of cancer and to establish a correct treatment strategy for such a complication, which still represents the second leading cause of death in cancer patients. ■
